Will Trikafta increase life expectancy?

Use of Trikafta could mean an increase in the life expectancy of cystic fibrosis patients, and for young children who begin the treatment early, “They might never have to experience the symptoms of cystic fibrosis in the same way prior to Trikafta,” Quinn said.

Is there a cure coming soon for CF?

Even with the promising research currently underway, new treatments or cures for CF are still likely years away. New treatments require years of research and trials before governing agencies will allow hospitals and doctors to offer them to patients.

Is Trikafta better than Symdeko?

The panel voted 14-0 that the clinical evidence was adequate to demonstrate greater net health benefit for Trikafta compared with both best supportive care and Symdeko for patients homozygous for the F508del mutation.

Does Kaftrio increase life expectancy?

One “unequivocal positive” for patient treatment, and potentially for increased life expectancy, was the introduction, late last year, of the modulator therapy Kaftrio (ivacaftor/tezacaftor/elexacaftor), the investigators said.

Why is Trikafta a breakthrough?

Unlike previously available modulator therapies, TRIKAFTA is the first approved three-drug combo that targets the Phe508del mutation, where the protein improperly folds, gets stuck in the cell, and ultimately degrades there without reaching the surface to function.

How many people are taking Trikafta?

More than 16,500 people age 6 years and older have been prescribed TRIKAFTA®

Is Trikafta a cure for cystic fibrosis?

Summary. Trikafta® is a highly effective therapy for the underlying cause of cystic fibrosis. It is approved for use in people with CF ages 6 and older who have at least one copy of the F508del mutation or certain mutations in the CFTR gene that are responsive based on lab data. It is not a cure for CF.

How well does Trikafta work?

Trikafta is a transformational drug that can treat up to 90% of Canadians with cystic fibrosis.

What is the death rate of cystic fibrosis?

Based on 2019 Registry data, the life expectancy of people with CF who are born between 2015 and 2019 is predicted to be 46 years. Data also show that of the babies who are born in 2019, half are predicted to live to be 48 years or older.

How long has Trikafta been around?

Vertex Pharmaceuticals developed the triple-combination therapy, which the U.S. Food and Drug Administration (FDA) approved in October 2019 to treat CF patients, ages 12 and older, with at least one F508del mutation.